🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Mabwell (Shanghai) Bioscience clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with Mabwell (Shanghai) Bioscience as lead sponsor. Synced 26 Sep 2026
23Current trials
16Recruiting now
13Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Mabwell (Shanghai) Bioscience is the lead sponsor of 23 current clinical trials in our China and USA registers. 16 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are 9MW2821, Toripalimab and 7MW3711. The most-studied condition is Urothelial Carcinoma.

ClinicalTrials.gov trials by status

  • Recruiting1670%
  • Not yet open417%
  • Active, closed313%

Trials by phase

  • Phase 1/2835%
  • Phase 1522%
  • Phase 3522%
  • Phase 2522%
01

Clinical trials sponsored by Mabwell (Shanghai) Bioscience

23 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
NCT06752746 · ClinicalTrials.gov ↗ · Polycythemia Vera
Phase 1 Recruiting 2024-03 China
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
NCT06592326 · ClinicalTrials.gov ↗ · Urothelial Carcinoma
Phase 3 Recruiting 2024-08 China
A Phase II Study of 9MW3811 in Patients With Pathological Scar
NCT07576608 · ClinicalTrials.gov ↗ · Scar
Phase 2 Recruiting 2025-12 China
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
NCT06908928 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer
Phase 1 Recruiting 2025-08 USA
First-in-human Study of 7MW4911 in GI Cancer
NCT07216560 · ClinicalTrials.gov ↗ · GI Cancers
Drug: 7MW4911
Phase 1/2 Recruiting 2026-01 USA
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
NCT06079112 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma
Phase 1/2 Recruiting 2023-09 China
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT06492005 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer
Phase 2 Recruiting 2024-07 China
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
NCT07314723 · ClinicalTrials.gov ↗ · Urothelial Carcinoma
Phase 2 Recruiting 2025-08 China
A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
NCT06772766 · ClinicalTrials.gov ↗ · Beta-Thalassemia
Phase 1 Recruiting 2024-12 China
A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07292714 · ClinicalTrials.gov ↗ · Chronic Obstructive Pulmonary Disease COPD
Drug: 9MW1911
Phase 2 Recruiting 2025-07 China
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
NCT07466160 · ClinicalTrials.gov ↗ · Solid Tumor
Phase 1/2 Recruiting 2026-02 China
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
NCT06196736 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma
Drug: 9MW2821
Phase 3 Recruiting 2023-12 China
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
NCT06692166 · ClinicalTrials.gov ↗ · Cervical Cancer
Drug: 9MW2821
Phase 3 Recruiting 2024-09 China
First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors
NCT07265622 · ClinicalTrials.gov ↗ · Solid Tumors
Drug: 7MW4911
Phase 1/2 Recruiting 2025-11 China
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
NCT05773937 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumors
Drug: 9MW2821
Phase 1 Recruiting 2022-06 China
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
NCT06823427 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
Phase 2 Recruiting 2025-01 China
9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors
NCT06926998 · ClinicalTrials.gov ↗ · Gynecological Malignancies
Drug: 9MW2821
Phase 1/2 Not yet open 2025-04 China
A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors
NCT06947226 · ClinicalTrials.gov ↗ · Solid Tumors
Phase 1/2 Not yet open 2025-04 China
A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT07556848 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Triple-negative Breast Cancer
Drug: 9MW2821
Phase 3 Not yet open 2026-05 China
A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy
NCT07831863 · ClinicalTrials.gov ↗ · Lung Squamous Cell Carcinoma
Phase 3 Not yet open 2026-10 China
Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors
NCT05990452 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1/2 Active, closed 2023-08 China
Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).
NCT06175351 · ClinicalTrials.gov ↗ · Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Drug: 9MW1911
Phase 1/2 Active, closed 2023-07 China
A Phase I Study of 9MW4113 Injection Versus Dupixent®
NCT07791342 · ClinicalTrials.gov ↗ · Healthy Participants
Drug: Dupilumab
Phase 1 Active, closed 2026-04 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Mabwell (Shanghai) Bioscience trials

13 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Mabwell (Shanghai) Bioscience trials

22 conditions
Urothelial Carcinoma3Advanced Urothelial Carcinoma2Solid Tumors2Triple Negative Breast Cancer1GI Cancers1Advanced Solid Tumor1Polycythemia Vera1Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)1Scar1Healthy Participants1Gynecological Malignancies1Triple-Negative Breast Cancer1Beta-Thalassemia1Chronic Obstructive Pulmonary Disease COPD1Locally Advanced or Metastatic Triple-negative Breast Cancer1Solid Tumor1Cervical Cancer1Lung Squamous Cell Carcinoma1Advanced Malignant Solid Tumors1Urothelial Carcinoma Bladder1Urothelial Carcinoma Recurrent1Urothelial Carcinoma of the Renal Pelvis and Ureter1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2114
Clinical trials in USA22

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Urothelial Carcinoma

SponsorTrials
UroGen Pharma4
Seagen, a wholly owned subsidiary of Pfizer2
ImmunityBio2
BeiGene2
Pacific Edge1
Sheng Zhang1

Sponsors with the most current trials registered for this condition.

06

Questions about Mabwell (Shanghai) Bioscience trials

How many clinical trials does Mabwell (Shanghai) Bioscience sponsor?

Mabwell (Shanghai) Bioscience is the lead sponsor of 23 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Mabwell (Shanghai) Bioscience trials recruiting?

Yes. 16 of its 23 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Mabwell (Shanghai) Bioscience testing?

Its current trials name 13 drugs and biologicals as interventions. The most frequent are 9MW2821 (10), Toripalimab (4), 7MW3711 (2), 7MW4911 (2) and 9MW1911 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.